BET inhibition decreases HMGCS2 and sensitizes resistant pancreatic tumors to gemcitabine.

Autor: Miller AL; Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL, USA., Fehling SC; Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL, USA., Vance RB; Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL, USA., Chen D; Department of Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, USA., Brown EJ; Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL, USA., Hossain MI; Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL, USA., Heard EO; Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL, USA., Andrabi SA; Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL, USA; Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA., Wang H; Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL, USA., Yang ES; Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, USA., Buchsbaum DJ; Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, AL, USA., van Waardenburg RCAM; Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL, USA., Bellis SL; Department of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL, USA., Yoon KJ; Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: kyoon@uab.edu.

Publikováno v: Cancer letters [Cancer Lett] 2024 Jun 28; Vol. 592, pp. 216919. Date of Electronic Publication: 2024 May 03.